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Autosomal dominant polycystic kidney disease (ADPKD) is
associated with a urine-concentrating defect attributed to
renal cystic changes. As PKD genes are expressed in the
brain, altered central release of arginine vasopressin could
also play a role. In order to help determine this we measured
central and nephrogenic components of osmoregulation in
10 adults and 10 children with ADPKD, all with normal
renal function, and compared them to 20 age- and gender-
matched controls. Overnight water deprivation caused a
lower rise in urine osmolality in the patients with ADPKD
than controls, reflecting an impaired release of vasopressin
and a peripheral defect in the patients. The reactivity of
plasma vasopressin to water deprivation, as found in
controls, was blunted in the patients with the latter showing
lower urine osmolality for the same range of plasma
vasopressin. The maximal urine osmolality correlated
negatively with total kidney volume. Defective
osmoregulation was confirmed in the children with ADPKD
but was unrelated to number of renal cysts or kidney
size. Thus, patients with ADPKD have an early defect in
osmoregulation, with a blunted release of arginine
vasopressin. This reflects expression of polycystins in
hypothalamic nuclei that synthesize vasopressin, and this
should be considered when evaluating treatments
targeting the vasopressin pathway in ADPKD.
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Autosomal dominant polycystic kidney disease (ADPKD) is
the most frequent inherited nephropathy, characterized by
the development of multiple cysts from every nephron
segment. The disease progresses slowly to renal failure and
end-stage renal disease in more than 70% of patients, kidney
and renal cyst growth being the strongest predictors of renal
function decline. Mutations in the two genes PKD1 and PKD2
account for 85 and 15% of the affected families, respectively.1
The PKD1 and PKD2 genes encode integral membrane
proteins, polycystin-1 and polycystin-2, which form a
complex localized in various cellular domains. The latter
include the primary cilium of renal tubular epithelial cells in
which the polycystins mediate calcium fluxes in response to
mechanical or chemical stimuli. Mutations in PKD1/PKD2
alter intracellular calcium homeostasis and lead to cystogen-
esis by a combination of increased cellular proliferation,
abnormal fluid secretion, and dedifferentiation.1–3
Several lines of evidence support a major role of increased
concentrations of 30-50-cyclic adenosine monophosphate
(cAMP) in the progression of renal cystic disease in
ADPKD.4,5 High cAMP levels in PKD cells lining the distal
nephron can result from a reduction in intracellular Ca2þ
concentration, which stimulates adenylate cyclase and
inhibits phosphodiesterase activity, but also from arginine
vasopressin (AVP) signaling through the vasopressin V2
receptor (V2R).1,4 The relevance of the V2R pathway in
ADPKD was demonstrated by inhibiting renal cyst develop-
ment in rodent models treated with V2R antagonists or high
water intake or by crossing PCK (Pkhd1-null) with AVP-null
(Brattleboro) rats.1,2,6 These results motivated the initiation
of a large, phase III clinical trial testing whether long-term
use of V2R antagonists effectively slows cystogenesis, 7 and of
pilot studies to evaluate the effect of water prescription in
patients with ADPKD.8,9
Thus far, the evidence of abnormal V2R-cAMP signaling
in ADPKD has essentially been obtained in vitro and in
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rodent models, most often in relation with cystogenesis.
However, early studies suggested that osmoregulation itself
may be affected in ADPKD. Defective urinary concentration
is frequently observed in patients with ADPKD10,11 and is
more severe in patients harboring large kidneys on
ultrasound analysis.12 A peripheral resistance to AVP has
been suggested, in view of higher AVP levels observed in
ADPKD patients at baseline and after hypertonic saline
infusion.13,14 The usual explanation for such peripheral
resistance to AVP is the existence of cystic lesions impairing
establishment of the interstitial osmotic gradient driving
water reabsorption in the distal nephron.1 However, impaired
urine concentration has also been described before major
cystic changes both in patients15 and rodent models of
ADPKD.16 Furthermore, haploinsufficiency in polycystin-1
has been associated with inappropriate antidiuresis and
central AVP release in a Pkd1 mouse model.17 Finally, both
PKD1 and PKD2 transcripts are abundantly expressed in
various regions of the brain,18 where their role(s) remain(s)
unknown. Thus, the exact nature of the urinary concentrat-
ing defect in ADPKD, the potential involvement of the
central release of AVP, as well as the timing of the defect and
its link to cystogenesis remain open questions.
In an effort to clarify the issue, we investigated the
osmoregulation parameters in two cohorts of adult and
pediatric ADPKD patients. The patients were included at an
early stage of disease and rigorously compared with age-
and gender-matched, non-affected family members
or controls. The urinary concentrating parameters were
investigated at baseline and following water deprivation, in
relation to plasma AVP, renal volume (measured by magnetic
resonance imaging, MRI), and blood pressure. We
also documented the expression of the PKD and AVP genes
in the mouse and human brain. Our results show that, at an
early stage, patients with ADPKD are characterized by a
defective osmoregulation that involves the central release
of AVP.
RESULTS
Clinical characteristics of the ADPKD patients and controls
The adult ADPKD population included seven women and
three men, aged 22 to 66 years, who were matched with
10 unaffected family members (Table 1). Body weight,
estimated glomerular filtration rate (eGFR), water, and NaCl
intake were similar in ADPKD patients and control subjects.
ADPKD patients had a significantly higher blood pressure
than controls. In all, 6 of 10 adult ADPKD patients were
treated with one to four antihypertensive drugs (mainly
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers, diuretics, and b-blockers), whereas no
control subject had hypertension.
The children ADPKD cohort included five girls and five
boys, aged 4–17 years, who were matched for age and gender
with 10 non-related healthy volunteers. Body weight, body
mass index, mean blood pressure, and eGFR were similar in
both groups (Table 1).
Osmoregulation parameters at baseline and after water
deprivation
Osmoregulation parameters (plasma and urine osmolality,
plasma level of AVP, urinary cAMP levels), as well as plasma
urea and creatinine and aldosterone levels were similar
in ADPKD patients and controls at baseline (Table 2).
Water deprivation (which induced a weight loss ofB12% in
both groups) induced a higher increase in plasma osmolality
in ADPKD patients than in controls (304±1.4 vs.
300±0.9mOsm/kg, respectively, P¼ 0.023). The maximal
urine osmolality (Umax, after overnight water deprivation)
was lower in ADPKD patients than in controls (710±68 vs.
920±47mOsm/kg, respectively, P¼ 0.020). Despite these
differences in plasma osmolality, plasma AVP levels remained
unchanged in ADPKD patients, contrasting with increased
values in controls (Table 2). Examination of the individual
parameters obtained at baseline and after water deprivation
revealed that the correlation between plasma osmolality and
plasma AVP, as observed in controls (Figure 1a), was blunted
in ADPKD patients (Figure 1b). In contrast, the reactivity
of plasma aldosterone to water deprivation was similar in
both groups.
To substantiate the relationship between the severity
of ADPKD and the impaired urinary concentration,
we obtained total kidney volume (TKV) measurements by
MRI at baseline in the cohort of adult ADPKD patients. The
TKV averaged 1026ml in the cohort (range: 450–2037ml).
Figure 2 shows that there was a negative correlation between
maximal urinary concentrating ability and renal volume:
patients with the largest kidneys had the most severe urinary
concentrating defect.
Table 1 | Clinical and biological parameters in the ADPKD
patients and controls
Adults ADPKD (N=10) CTRL (N=10) P
Age (years) 44.4±4.1 40.8±3.3 0.5
Gender 3M/7F 3M/7F
Body weight (kg) 70.6±4.3 68.3±3.4 0.69
Mean blood pressure (mmHg)a 104±2.9 95±2.9 0.041
eGFR (ml/min) 129±11.0 117±11.0 0.355
Water intake (ml per 24 h) 2222±189 2071±214 0.603
NaCl intake (g per 24 h)b 9.24±0.89 9.24±1.22 1.000
Children ADPKD (N=10) CTRL (N=10) P
Age (years) 11.6±1.3 11.4±1.4 0.915
Gender 5M/5F 5M/5F
Body weight (kg) 40.6±4.8 41.1±6.4 0.954
BMI (kg/m2)c 16.9±0.6 18.0±1.3 0.463
Mean blood pressure (mmHg)a 89.2±3.1 85.9±3.9 0.517
eGFR (ml/min per 1.73m2) 173.5±5.2 165.2±12.0 0.534
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; BMI, body
mass index; CTRL, control; eGFR, estimated glomerular filtration rate; F, female;
M, male.
aMean blood pressure was calculated as the half of the sum of systolic and
diastolic basal blood pressure in mmHg, obtained in duplicate.
bNaCl intake was estimated from the 24-h urine collection (natriuria (mmol/l) 24-h
urine volume/17).
cBMI was the rapport of the weight on the squared height.
1122 Kidney International (2012) 82, 1121–1129
or ig ina l a r t i c l e TA Ho et al.: Defective release of AVP in ADPKD
Central and peripheral response to water deprivation
Osmoregulation is a complex mechanism that involves
central and peripheral responses leading to the adjustment
of urinary osmolality in response to changes in plasma
osmolality. The combination of blunted increase in plasma
AVP despite increased plasma osmolality (Table 2, Figure 1)
suggested a central defect in response to water deprivation in
ADPKD patients. However, the correlation between the
urinary concentrating defect and kidney volume (Figure 2)
suggested a peripheral component as well.
To characterize the peripheral response to AVP, we
analyzed Umax as a function of plasma AVP (Figure 3). A
Table 2 | Osmoregulation parameters in adult ADPKD patients and controls
ADPKD (N=10) CTRL (N=10)
Baseline Water deprivation Baseline Water deprivation
P osm (mOsm/kg) 295±1.8 304±1.4a,b 296±1.8 300±0.9
P AVP (pg/ml) 1.50±0.17 1.78±0.22 1.47±0.11 2.02±0.20a
P urea (mg/dl) 33.0±2.3 37.0±2.1 28.7±2.2 34.3±2.4
P creatinine (mg/dl) 0.80±0.05 0.76±0.06 0.69±0.06 0.73±0.06
P aldosterone (nmol/l) 0.25±0.05 0.36±0.08 0.27±0.04 0.33±0.08
U osm (mOsm/kg) 393±77 710±68a,b 351±65 920±47a
U cAMP (mmol/l) 1.48±0.19 2.40±0.36a 1.49±0.33 3.83 ±0.75a
U cAMP/creat (nmol/mg) 3.00±0.57 1.73±0.22a 2.76±0.36 1.56±0.31a
Body weight (kg) 70.6±4.3 69.7±4.3a 68.3±3.4 67.5±3.4a
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; AVP, arginine vasopressin; cAMP, cyclic adenosine monophosphate; creat, creatinine; CTRL, control;
Osm, osmolality; P, plasma; U, urine.
aWater deprivation vs. baseline (Po0.05).
bADPKD vs. CTRL (Po0.05).
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Figure 1 |Relationship between plasma osmolality and vasopressin levels in autosomal dominant polycystic kidney disease
(ADPKD) and controls (CTRLs). The correlation of individual parameters at baseline and after water deprivation shows that the positive
relationship between plasma osmolality and plasma vasopressin (AVP), as observed in (a) controls, is blunted in (b) ADPKD patients.
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Figure 2 |Correlation beween total renal volume and urinary concentrating ability in autosomal dominant polycystic kidney
disease (ADPKD) patients. There is an inverse correlation between maximal urine concentration (Umax) and total renal volume measured
by magnetic resonance imaging (MRI). The correlation is illustrated by MRI images of the kidneys of two representative patients: a 42-year-
old man with few renal cysts shows a high urinary concentrating ability (959mOsm/kg), whereas a 40-year-old woman with large
cystic kidneys shows a low urinary concentrating ability (464mOsm/kg).
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significant correlation between plasma AVP and Umax was
observed in each group, but the shift of the linear regression
indicated that a higher plasma AVP level is needed to achieve
the same Umax in ADPKD vs. control (CTRL; Figure 3).
Furthermore, a lower proportion of ADPKD patients
compared with controls (4/10 ADPKD patients vs.
9/10 controls, P¼ 0.019) reached a Umax of 800mOsm/kg
(corresponding to standard expected value after water
deprivation). These data reveal that Umax, which reflects
the action of AVP on its V2R target and downstream
effectors, is deficient in ADPKD. Thus, ADPKD patients
present a defective peripheral response to AVP, located
downstream of the V2R in the principal cells of the collecting
ducts.
Response to water loading
A standardized acute water loading test was performed in
adult ADPKD patients and controls to assess the capacity of
the kidney to dilute urine (Figure 4). The ingestion of water
led to an abrupt increase in urinary output (Figure 4a),
paralleled by a sharp decrease in urine osmolality (Figure 4b)
during the first 2 hours of the test, with subsequent
recovery during the 3 h. The kinetic and mean values of
these parameters were similar in ADPKD and control groups,
demonstrating that the diluting capacity was intact in these
ADPKD patients.
Osmoregulation in children with ADPKD
Children with ADPKD and controls underwent a simplified
protocol to investigate osmoregulation parameters following
an overnight water deprivation. The biological parameters
at the end of water deprivation are shown in Table 3. As
in adults, maximal urine osmolality was lower in ADPKD
children than in controls (Figure 5), despite a trend for
higher plasma osmolality (298±1.1 vs. 295±0.7mOsm/kg),
whereas plasma creatinine and eGFR values were similar.
ADPKD children also showed lower plasma urea levels, which
may suggest a decreased acute vasopressin effect on the
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Figure 3 |Relationship between plasma vasopressin and
maximal urine osmolality in autosomal dominant polycystic
kidney disease (ADPKD) patients and controls (CTRLs). The
peripheral response to vasopressin was assessed by analyzing
maximal urine concentration (Umax, after overnight water
deprivation) as a function of plasma AVP. The dotted line
represents the expected Umax in these conditions (800mOsm/
kg). Black squares represent ADPKD patients, and open squares
represent CTRL subjects. The two significant regression lines in
CTRL (r2: 0.58; P¼ 0.01) and ADPKD (r2: 0.46; P¼ 0.03) are shown,
with a displacement to the right indicating that a higher plasma
AVP level is needed to achieve the same Umax in ADPKD vs. CTRL.
For a similar range of plasma AVP, only 4/10 ADPKD patients vs.
9/10 CTRL subjects reached a Umax 4800mOsm/kg (P¼ 0.019).
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Figure 4 |Acute water loading in autosomal dominant
polycystic kidney disease (ADPKD) patients and controls
(CTRLs). A similar response to acute water loading—(a) increased
urine output and (b) decreased urine osmolality (Uosm)—is
observed in both groups. Both the timing and magnitude of
changes are similar in ADPKD vs. controls.
Table 3 | Biological parameters after water deprivation in
pediatric ADPKD patients and controls
ADPKD (N=10) CTRL (N=10) P
P osm (mOsm/kg) 298±1.1 295±0.7 0.108
P AVP (pg/ml) 1.92±0.38 2.13±0.28 0.659
P creatinine (mg/dl) 0.53±0.05 0.56±0.06 0.758
P urate (mg/dl) 4.03±0.27 4.73±0.28 0.091
P urea (mg/dl) 25.0±1.2 32.7±2.0 0.004
P aldosterone (nM) 0.18±0.03 0.25±0.04 0.197
U osm (mOsm/kg) 872±53 1041±47 0.029
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; AVP, arginine
vasopressin; CTRL, control; Osm, osmolality; P, plasma; U, urine.
All parameters were obtained after overnight water deprivation.
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kidney, with lower urea recirculation and less efficient urine
concentration.
This simplified protocol suggested that ADPKD children
show both central and peripheral defects in osmoregulation.
For a similar range of plasma AVP levels, 7/10 ADPKD children
had a plasma osmolality higher than 296mOsm/kg (the mean
value for the two groups), whereas only 4/10 controls reached
that value, suggesting a central defect into the release of
AVP. For a similar range of plasma AVP levels, only 4/10
ADPKD children reached the mean maximal urine osmolality
(957mOsm/kg), whereas 7/10 control children exceeded that
value. On ultrasound examination, there was no correlation
between the number of renal cysts or bilateral kidney length
(even normalized for height, weight, or body surface) and
urinary osmolality in ADPKD children (data not shown).
Expression of PKD1 and PKD2 in osmoregulatory regions
of the brain
The expression profile of PKD1 and PKD2 in the osmo-
regulatory regions of the brain has not been clearly
demonstrated. A search of the available databases (mouse
and human Allen Brain Atlas) revealed that, in comparison
with the abundant Avp transcript, Pkd1 and Pkd2 are clearly
enriched in the paraventricular, suprachiasmatic, and su-
praoptic hypothalamic nuclei of the adult mouse brain
(Figure 6a). Similarly, a significant expression level of PKD1
and PKD2 was detected by microarray analysis in the
AVP-expressing paraventricular and supraoptic nuceli of the
hypothalamus in the human brain (Figure 6b). A significant
expression of Pkd1 and Pkd2 was also identified in scattered
neurons forming the subfornical organ and vascular organ of
the lamina terminalis, two regions involved in thirst response
(Supplementary Figure S1 online).
DISCUSSION
The results presented here demonstrate that patients with
ADPKD show a significant defect in osmoregulation affecting
both the release of AVP in response to plasma osmolality
(central component) and the V2R-mediated response
(nephrogenic component). Defective osmoregulation was
observed in adult and pediatric ADPKD patients early in the
course of disease, whereas the capacity to dilute urine
remained intact. The alteration in the central release of AVP
can be explained by a significant expression of PKD1 and
PKD2 together with AVP in the hypothalamic nuclei.
The existence of a urinary concentrating defect in ADPKD
was first described almost 40 years ago10 and was subse-
quently verified in several studies.8,11,12,15 The present results
confirm and extend these reports, showing that the
defect occurs early in the disease course as evidenced in
children and adults with intact GFR, in the absence of
hypokalemia or acid–base abnormalities. The extent of the
urinary concentrating defect is clearly correlated with TKV as
assessed by MRI in adults. In contrast, the magnitude of the
defect could not be correlated with the number of renal cysts
or renal length obtained by ultrasound examination in
ADPKD children. The presence of cysts or their number in
the early stage of ADPKD is thus not a prerequisite for the
osmoregulation defect documented here. This conclusion is
in fact supported by developmental studies in diphenlythia-
zole-induced rats16 and cpk mice,19 in which the urinary
concentrating defect precedes the development of renal cysts.
More than structural changes in the collecting ducts, a
functional defect in cellular or interstitial processes has been
evoked.19 The latter hypothesis is also supported by the
altered reactivity to AVP observed in the haploinsufficient
Pkd1 mouse model, which does not show renal cysts.17
Overnight water deprivation revealed that, in comparison
with controls, ADPKD patients had a higher increase in
plasma osmolality contrasting with a blunted release of AVP
(Table 2). The relationship between plasma osmolality and
AVP levels, combining data at baseline and after water
deprivation, was blunted in ADPKD patients (Figure 1).
In agreement with Danielsen et al.,13 baseline plasma AVP
levels were similar in ADPKD and CTRL, reflecting similar
plasma and urine osmolality and similar water and NaCl
intake in both groups. Recently, Meijer et al.20 showed a
significant correlation between plasma osmolality and
copeptin, a surrogate marker of AVP, at baseline, in a cohort
of ADPKD adults with CKD stages 1 to 4. The fact that
plasma copeptin levels are influenced by GFR may explain
why the baseline copeptin levels reported in the latter study
are higher (median: 7.0 pmol/l) than in controls from the
PREVEND study (median: 4.7 pmol/l).21 This could possibly
also explain the correlation between plasma copeptin and
osmolality because of the contribution of urea to measured
osmolality. Importantly, no healthy controls were investigated
by Meijer et al.,20 and the reactivity to water deprivation was
also not tested. Taken together, these elements suggest that
ADPKD patients have a central defect altering the release of
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Figure 5 |Urine osmolality after overnight water deprivation
in children with autosomal dominant polycystic kidney
disease (ADPKD) and controls (CTRLs). Urine osmolality was
obtained in 10 pairs of children with ADPKD vs. age- and
gender-matched controls. The maximal urine osmolality (Umax) is
significantly higher in CTRL than in ADPKD children (P¼ 0.029).
*Po0.05, CTRL vs. ADPKD.
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AVP in response to increased plasma osmolality levels caused
by water deprivation.
What could be the molecular counterpart of such a central
defect? ADPKD is not classically associated with functional
defects in the central nervous system. However, both PKD1
and PKD2 genes show a predominant neural expression
during development, with high expression levels (particularly
for PKD1) still detected in the adult brain.18 Similarly, the
Pkd1 transcript has been detected in intracranial arteries,22
and polycystin-1 has been shown to be expressed in ciliated
structures in the lateral and third ventricles of the mouse
brain.23 Data extracted from the Allen Brain Atlas show that,
in fact, both Pkd1/Pkd2 (mouse) and PKD1/PKD2 (human)
transcripts are expressed in the supraoptic, suprachiasmatic,
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Figure 6 | Expression of polycystic kidney disease (PKD) genes in the hypothalamus. (a) Expression of Pkd1, Pkd2, and Avp genes
(in situ hybridization) in the hypothalamic nuclei of the adult mouse. Data compiled from the Mouse Allen Brain Atlas (http://mouse.
brain-map.org/). (b) Expression of PKD1, PKD2, and AVP in human brain. The expression profiles for AVP, PKD1, and PKD2 (microarray) in
paraventricular nucleus (PVN) and supraoptic nucleus (SON) were obtained from Allen Brain Atlas (http://human.brain-map.org). The
microarray data sets are presented as a matrix with brain structure, using a ‘heat map’ format in which the colors correspond to a
normalized (z-score) expression level of each probe in coronal sections of magnetic resonance imaging (MRI) space around the
hypothalamus. z is negative when the raw score is below the population mean and positive when above. The data shown in the Table are
log2 expression values of each probe in each brain area. Expression data of AVP: donor¼ 10021 and probes¼ 1058921; expression data of
PKD1: donor¼ 10021 and probes¼ 1053025; expression data of PKD2: donor¼ 10021 and probes¼ 1053021. PVN, paraventricular nucleus;
SCN, suprachiasmatic nucleus; SON, supraoptic nucleus.
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and paraventricular nuclei that synthesize and release AVP in
response to a rise in plasma osmolality (Figure 6).
Intrinsic osmosensitivity of the vasopressin-containing
neurons is conferred by mechanosensitive cation channels
that include TRPV1 and TRPV4.24 There is evidence that
polycystin-2 interacts with TRPV4 to form a mechanosensor
driving calcium transients in vitro.25 It is interesting to note
that mice lacking TRPV4 show a lower increase in circulating
AVP upon hypertonic stress while being more hyperosmolar
than wild-type littermates,26 i.e., a similar phenotype to that
of the ADPKD patients examined here. Recently, it was
shown that Trpv4-null mice also show defective activation of
an osmosensitive sensory system in the liver.27 Although the
exact roles of TRPV1 and TRPV4 in hypertonicity sensing
remain debated,28 one could hypothesize that a defect in
the multiprotein complex transducing calcium-dependent
information in vasopressin neurons could be defective
in ADPKD patients. Alternatively, the functional loss of
polycystins could affect the level of AVP in hypothalamic
neurons, or interfere with the clock control of AVP release in
the late sleep period.29 A potential role of the polycystins in
thirst could also be suggested, based on the detection of their
transcripts in the subfornical organ and vascular organ of the
lamina terminalis regions of the mouse brain. At any rate,
this extrarenal manifestation of ADPKD suggests a role for
polycystins in the hypothalamus. This could be relevant for
the use of vasopressin antagonists, known to be associated
with increased levels of endogenous AVP.30
In addition to the central component, the ADPKD
patients investigated here show manifestations of peripheral
resistance to AVP. Maximal urine osmolality after water
deprivation was consistently lower, despite a similar range of
plasma AVP. The shifted relationship between plasma AVP
and Umax in ADPKD patients and the lower proportion of
patients reaching a Umax value4800mOsm/kg concur with
this conclusion. In addition, the magnitude of the concen-
tration defect was significantly correlated with TKV obtained
by MRI. The exact nature of the peripheral defect in
AVP-V2R signaling in ADPKD kidneys remains uncertain.
In the absence of cAMP measurement in the renal papilla, the
value of urinary cAMP as an indicator of the V2R response is
questionable, as this parameter may essentially reflect the
activity of PTH in the proximal tubule.31
On the basis of evidence suggesting that increased cAMP
levels are involved in cyst progression, the ingestion of
supplemental water is increasingly considered as a potential
treatment for ADPKD.6 A normal capacity to dilute urine
was observed in two preliminary studies evaluating the effect
of water prescription in a total of 21 ADPKD patients with
preserved eGFR (460ml/min per 1.73m2).8,9 Our report of
an intact urinary diluting ability over a 3-h follow-up in
ADPKD patients exposed to an acute water load supports
these results. Furthermore, the detailed kinetics suggest that
the rapid lowering of the circulating AVP is totally preserved
in ADPKD patients (Figure 4). Hence, the central defect
discussed above indeed concerns the coupling between
increased plasma osmolality and release of AVP by hypotha-
lamic neurons.
Several limitations of our study should be acknowledged.
First, the study population is small and selected, with
limited statistical power. However, we feel that the rigorous
investigation protocol and the inclusion of age- and gender-
matched controls (with unaffected siblings for the adult
population) bring an added value to the analysis. Second,
osmoregulatory parameters were measured once at baseline,
and thus we could not assess the effect of variation over time.
The facts that the background noise is greater with a single
measure and that the measure was obtained in exactly similar
conditions in both groups, before and after reactivity testing,
rather support the relevance of our data. Third, we did not
use the method of acute hypertonic saline injection to assess
the central release of AVP. Instead, the use of a controlled
water deprivation test was considered more physiological and
less invasive in a population that included a majority of
hypertensive patients deprived from their antihypertensive
medications for 3 weeks at the time of investigation. Ethical
considerations were also guiding the choice of a much
simplified protocol in the children cohort. Additional studies
will thus be necessary to address these limitations and
confirm our findings.
In conclusion, the present study shows that patients with
ADPKD show both a central and peripheral defect in
osmoregulation early in the course of the disease. The central
defect, which parallels the expression of PKD genes in
hypothalamic neurons that synthesize and release AVP, is a
novel extrarenal manifestation of ADPKD. These data provide
insights into the role of polycystins in the brain and are relevant
when considering treatments targeting AVP in ADPKD.
MATERIALS AND METHODS
Patients and controls
Twenty ADPKD patients, 10 adults and 10 children, with a normal
renal function (eGFRX60ml/min) were included in the study. The
clinical diagnosis of ADPKD was assigned according to the
ultrasonographic criteria of Ravine32 in patients with a familial
history of ADPKD. Controls for the ADPKD adults were age- and
gender-matched non-affected members of ADPKD families, in
which the disease had been excluded by negative renal ultrasonog-
raphy after the age of 30 years or by linkage analysis. Controls for
the ADPKD children were unrelated healthy children, matched for
age and gender, with no familial history of renal disease. The study
protocol has been approved by the Ethics Committee of the UCL
Medical School, Brussels; adult study subjects or the parents of the
pediatric study subjects gave written informed consent.
Investigation protocol in adults and children
Adult patients with ADPKD and controls underwent a screening visit
3 to 4 weeks before a baseline evaluation that was immediately
followed by an overnight (16 h) water deprivation test and an acute
water loading test over a period of 2 days. Patients taking angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers, or
diuretics stopped these medications 3 weeks before the baseline visit.
Subjects were allowed to eat normally during the investigations.
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Clinical parameters, urine, and blood samples were collected at
baseline and at the end of the water deprivation. The water loading test
consisted of the ingestion of 20ml/kg body weight tap water in 30min,
followed by the hourly determination of urine flow and urine
osmolality for the next 3 h. TKV was determined by magnetic
resonance imaging (Achieva 3.0T TX MRI, Philips Healthcare, Best,
The Netherlands).
For ethical and technical reasons, the protocol was considerably
simplified in children. Children taking angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers or diuretics were excluded
from the study, because interruption or modification in their
treatment was not considered feasible. Children had no baseline
evaluation, but only one visit to collect blood and urine samples at the
end of a 12-h overnight water deprivation. Kidney length and the
number of cysts were determined by renal ultrasonography (ATL IU22
Ultrasound Machine, Philips Healthcare) in ADPKD children.
Clinical and biological analyses
Blood pressure, body weight, urine output, plasma, and urine
osmolality were assessed at baseline, after water deprivation, and
during the water loading test. Urinary concentrating ability was
assessed by maximal urine osmolality (Umax) reached at the end of
water deprivation. Plasma levels of urea, creatinine, sodium,
potassium, chloride, calcium, and proteins were measured at
baseline and after water deprivation, using routine laboratory
analyses (Synchron CX5, Beckman-Coulter, Fullerton, CA). The
eGFR was calculated using the Cockcroft formula in adults, and by
the Schwartz adapted formula33 in children. The concentrations of
creatinine, sodium, and protein were measured on 24-h urine
collections in adults, and on a second morning fasting urine sample
in children. Plasma and urine osmolality was measured using a Fiske
Osmometer (Needham Heights, MA). Plasma levels of AVP were
determined in duplicate by radioimmunoassay34 (Tenon Hospital,
Paris, France). Plasma levels of renin were determined by enzyme
immunoassay (Liaison automate, DiaSorin, Anderlecht, Belgium),
plasma aldosterone by radioimmunoassay (TKAL2, Siemens, Brussels,
Belgium), and urinary cyclic AMP by enzyme immunoassay (Sigma-
Aldrich, Bornem, Belgium).
AVP and PKD gene expression in mouse and human brain
The expression pattern of mouse (Pkd1, Pkd2, and Avp) and human
(PKD1, PKD2, and AVP) genes was obtained from the appropriate
sections of the Allen Brain Atlas (http://mouse.brain-map.org/ and
http://human.brain-map.org/, respectively).
Statistical analysis
Data are means±standard error of the mean (s.e.m.). Comparisons
between groups were performed using two-tailed unpaired t-test.
Bivariate correlation and w2 test were used for parameter correla-
tions. All statistical analyses were performed using the SPSS 15.0
software (Brussels, Belgium). All tests were two-tailed, and Po0.05
was considered significant.
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